{"slug":"vilon","seoKey":"vilon","displayName":"Vilon","codes":["KE","AB-0","AB-17"],"synonyms":["Lys-Glu","KE dipeptide","H-Lys-Glu-OH","L-lysyl-L-glutamic acid","lysylglutamic acid (the PubChem entry title and the FDA substance name)","Вилон (the Russian spelling)","Vilon / Вилон (Russian trade name)"],"identifiers":{"cas":"45234-02-4","pubchemCid":7010502,"unii":"H34V7IM5ML","inchikey":"UGTZHPSKYRIGRJ-YUMQZZPRSA-N","chemblId":"CHEMBL365790","wikidataQid":"Q27144733","formula":"C11H21N3O5","molecularWeight":275.3,"sequence":"KE"},"legalClass":"research_chemical","approvals":[{"market":"US","status":"not_approved","note":"Not approved. No application record and no drug label were found on 2026-09-17, by trade name and by chemical name alike; the labelling database returned only an unrelated skin-barrier product whose name merely contains the same letters, while a control query returned two matches, so the interface was working. The federal substance database does carry the compound as a substance entry, with a unique ingredient identifier that lists the trade name among its names, but that is a pure substance identifier and means no authorisation and no medicinal assessment whatsoever. The substance has never been nominated for the compounding bulks list, whose full text was checked; the only remotely similar entry is a different compound. US distribution runs through the research-chemical channel under a not-for-human-use label.","source":"https://api.fda.gov/drug/drugsfda.json?search=openfda.brand_name:%22vilon%22"},{"market":"EU","status":"not_approved","note":"No centralised marketing authorisation, no assessment report and no trace of a withdrawn application. The register search is JavaScript-driven and produced no machine-readable result list on 2026-09-17, so the finding rests additionally on the absence of an international non-proprietary name and of a classification code. No novel-food authorisation for this dipeptide was found either, though the catalogue itself was not machine-readable.","source":"https://www.ema.europa.eu/en/medicines?search_api_fulltext=vilon"},{"market":"DE","status":"not_approved","note":"Neither a national nor an EU marketing authorisation exists, so the injectable form traded in the West is an unauthorised medicinal product and may not be placed on the market. The Russian food-supplement status of the oral capsule creates no marketability here, and certainly none for an injection. The substance is not named in the schedule to the Anti-Doping Act, whose section on peptide hormones, growth factors, related substances and mimetics lists what it covers by name and exhaustively; a dipeptide of two ordinary amino acids falls under none of those items. Sporting rules are unaffected by that.","source":"https://www.gesetze-im-internet.de/antidopg/anlage.html"},{"market":"UK","status":"not_approved","note":"No marketing authorisation known. The product register returned only the empty scaffold of its results page on 2026-09-17, and a control query with an approved active ingredient produced no evaluable hit either, so the interface as a whole was unusable and not just the query for this substance. The negative finding is NOT independently robust: it rests on the Union-wide picture and on the absence of an international non-proprietary name and classification code.","source":"https://products.mhra.gov.uk/search/?search=vilon"},{"market":"AU","status":"not_approved","note":"Not found in the register and not named in the poisons standard, as far as could be established. A direct register query was technically impossible on 2026-09-17: the interface dropped the connection twice, so the negative finding on the name is weak. The legal consequence is not: a therapeutic good without a register entry is not marketable in Australia, and there is no trade name or international non-proprietary name under which an entry could exist.","source":"https://www.tga.gov.au/resources/artg"},{"market":"CA","status":"not_approved","note":"No marketing authorisation, no drug identification number and no natural product number. On 2026-09-17 the query by brand name returned only an unrelated skin-barrier ointment whose name contains the same letters, and the query by active ingredient returned an empty array, while a control query for an authorised product returned the expected record, so the interface was working.","source":"https://health-products.canada.ca/api/drug/drugproduct/?lang=en&type=json&brandname=vilon"},{"market":"CH","status":"not_approved","note":"No marketing authorisation known. The page carrying the list of authorised medicines was unreachable under its known address on 2026-09-17, so no register extract could be produced. The negative finding rests on the absence of an international non-proprietary name, of a classification code and of any authorisation in the markets that could be checked.","source":"https://www.swissmedic.ch/"}],"devStage":"preclinical","strongestEvidence":"observational","wada":{"status":"prohibited","section":"S0","listYear":2026,"source":"https://www.wada-ama.org/en/prohibited-list"},"trials":[],"sameAs":["https://pubchem.ncbi.nlm.nih.gov/compound/7010502","https://www.wikidata.org/wiki/Q27144733","https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL365790/"],"lastVerified":"2026-09-17","version":"1.0","published":true,"locale":"en","title":"Vilon: what the studies show, status and safety","summary":"Vilon is a synthetic peptide of two amino acids, lysine and glutamic acid, from a St Petersburg institute that calls such molecules bioregulators. The same compound is catalogued as an ordinary human metabolite. No measurement of what happens to it in a body exists in any species. Its developers report that it breaks down faster than the three peptides they compared it against. It is approved as a medicine nowhere, and no trial in people has been registered.","updated":"2026-09-17","url":"https://mypep.app/peptides/vilon"}